![Alpha TAU Enrolls Its First Patient in Combination Trial of Alpha DaRT™ & Pembrolizumab (Keytruda) - JLM-BioCity Alpha TAU Enrolls Its First Patient in Combination Trial of Alpha DaRT™ & Pembrolizumab (Keytruda) - JLM-BioCity](https://jlm-biocity.org/wp-content/uploads/2021/11/20211103-AlphaTAU-banner-banner.jpg)
Alpha TAU Enrolls Its First Patient in Combination Trial of Alpha DaRT™ & Pembrolizumab (Keytruda) - JLM-BioCity
![Initial Safety and Tumor Control Results From a “First-in-Human” Multicenter Prospective Trial Evaluating a Novel Alpha-Emitting Radionuclide for the Treatment of Locally Advanced Recurrent Squamous Cell Carcinomas of the Skin and Head Initial Safety and Tumor Control Results From a “First-in-Human” Multicenter Prospective Trial Evaluating a Novel Alpha-Emitting Radionuclide for the Treatment of Locally Advanced Recurrent Squamous Cell Carcinomas of the Skin and Head](https://ars.els-cdn.com/content/image/1-s2.0-S0360301619340404-gr2.jpg)
Initial Safety and Tumor Control Results From a “First-in-Human” Multicenter Prospective Trial Evaluating a Novel Alpha-Emitting Radionuclide for the Treatment of Locally Advanced Recurrent Squamous Cell Carcinomas of the Skin and Head
![Alpha Tau Medical on Twitter: "In early February, we treated our 1st Alpha DaRT patient at Hadassah Medical Center Hospital in #Jerusalem. The procedure was carried out on a #SCC tumor on Alpha Tau Medical on Twitter: "In early February, we treated our 1st Alpha DaRT patient at Hadassah Medical Center Hospital in #Jerusalem. The procedure was carried out on a #SCC tumor on](https://pbs.twimg.com/media/EvJV6i0XcAI63M9.jpg)